LETTER TO THE EDITOR

Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy

Jennifer L. Crombie,[1*] Caron A. Jacobson,[1*] Robert Redd,[1] Geoffrey Shouse,[2] Alex F. Herrera,[2] Victor A. Chow,[3,4] Jordan Gauthier,[3,4] Erin Mullane,[3,4] Kirk Cahill,[5] Justin Kline,[5] Jason Romancik,[6] Jonathon B. Cohen,[6] Anna Saucier,[1] Roch Houot,[7] Philippe Armand[1] and Brian Hess[8]

[1]Dana-Farber Cancer Institute, Boston, MA, USA; [2]City of Hope National Medical Center, Duarte, CA, USA; [3]Fred Hutchinson Cancer Research Center, Seattle, WA, USA; [4]University of Washington, Seattle, WA, USA; [5]University of Chicago, Chicago, IL, USA; [6]Emory University, Atlanta, GA, USA; [7]University Hospital of Rennes, Rennes, France and [8]Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

**JLC and CAJ contributed equally as first authors*

Correspondence:
JENNIFER CROMBIE - Jennifer_Crombie@dfci.harvard.edu

https://doi.org/10.3324/haematol.2022.282345

Supplemental Figures:

Supplemental Figure 1: OS following CAR T-cell therapy
A) OS among entire cohort B) OS among patients who received axi-cel versus tisa-cel C) OS among patients with a CMR versus PMR/SD at 1 month D) OS among patients with Deauville 1/2, 3, 4, and 5.

Supplemental Figure 2: Predictors of relapse following CAR T-cell therapy
A) Forest plot demonstrating univariate predictors of relapse among initial responders B) Forest plot demonstrating multivariate predictors of relapse among patients with a DS 4 or less.

Supplemental Figure 1:



Supplemental Figure 2: